Research programme: anticancer antibody therapeutics - Adimab/Merrimack PharmaceuticalsAlternative Names: MM-131; Signaling inhibitors
Latest Information Update: 12 Jan 2017
At a glance
- Originator Adimab
- Developer Adimab; Merrimack Pharmaceuticals
- Class Antibodies; Bispecific antibodies
- Mechanism of Action Epithelial cell adhesion molecule inhibitors; Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer